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Objectives: Thiamin deficiency is highly prevalent in patients with 
sepsis, but the mechanism by which sepsis induces thiamin defi-
ciency is unknown. This study aimed to determine the influence 
of various severity of sepsis on carrier-mediated intestinal thiamin 
uptake, level of expressions of thiamin transporters (thiamin trans-
porter-1 and thiamin transporter-2), and mitochondrial thiamin 
pyrophosphate transporter.
Design: Randomized controlled study.
Setting: Research laboratory at a Veterans Affairs Medical Center.
Subjects: Twenty-four Sprague-Dawley rats were randomized into 
controls, mild, moderate, and severe sepsis with equal number of 
animals in each group.
Interventions: Sepsis was induced by cecal ligation and punc-
ture with the cecum ligated below the cecal valve at 25%, 50%, 
and 75% of cecal length, defined as severe, moderate, and mild 
sepsis, respectively. Control animals underwent laparotomy only.
Measurements and Main Results: After 2 days of induced sep-
sis, carrier-mediated intestinal thiamin uptake was measured 
using [3H]thiamin. Expressions of thiamin transporter-1, thiamin 
transporter-2, and mitochondrial thiamin pyrophosphate trans-
porter proteins and messenger RNA were measured. Proinflam-
matory cytokines (interleukin-1β and interleukin-6) and adenosine 
triphosphate were also measured. Sepsis inhibited [3H]thiamin 
uptake, and the inhibition was a function of sepsis severity. Both 
cell membrane thiamin transporters and mitochondrial thiamin 
pyrophosphate transporter expression levels were suppressed; 
also levels of adenosine triphosphate in the intestine of animals 
with moderate and severe sepsis were significantly lower than 
that of sham-operated controls.
Conclusions: For the first time, we demonstrated that sepsis inhib-
ited carrier-mediated intestinal thiamin uptake as a function of 
sepsis severity, suppressed thiamin transporters and mitochon-
drial thiamin pyrophosphate transporter, leading to adenosine tri-
phosphate depletion. (Crit Care Med 2016; XX:00–00)
Key Words: intestinal thiamin uptake; mitochondria; sepsis; thiamin 
deficiency; thiamin pyrophosphate; thiamin transporter
The active form of thiamin, thiamin pyrophosphate, rep-resents ~85–90% of total cellular thiamin, and is gener-ated exclusively in the cytoplasm and transported into 
the mitochondria for utilization of cellular metabolic process. 
Thiamin pyrophosphate is indispensable for normal mito-
chondrial function and structural integrity due to its involve-
ment as a cofactor in oxidative energy metabolism, adenosine 
triphosphate (ATP) production, and maintenance of cellular 
redox state by reducing cellular oxidative stress (1). Thus, low 
intracellular levels of thiamin leads to impairment in oxidative 
energy metabolism (acute energy failure), a propensity for oxi-
dative stress, and eventually apoptosis.
In critically ill adult and pediatric patients, thiamin defi-
ciency is highly prevalent, ranged from 20% to 70% (2–4). In 
one retrospective study (5), the mortality rate of critically ill 
patients with thiamin deficiency was 72% compared with 44% 
without the deficiency. Thiamin deficiency appears to contrib-
ute to the high mortality, yet the risk factor(s) contributing to 
the deficiency were not investigated. In critically ill patients 
with sepsis, sepsis has been identified as an important risk fac-
tor for thiamin deficiency (2–4). However, the extent by which 
sepsis leads to thiamin deficiency is unknown. Thiamin is not 
synthesized endogenously, but has to be obtained exogenously 
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from nutrient via transport across the intestinal cell mem-
brane, or from the circulation via transport to other organs. 
The cell membrane thiamin transporters (THTRs), THTR-1 
(encoded in SLC19A2 gene) and THTR-2 (encoded in SLC19A3 
gene), mediate intestinal thiamin transport process, whereas 
the uptake of thiamin pyrophosphate into the mitochondria 
occurs via a carrier-mediated mechanism that involves the 
mitochondrial thiamin pyrophosphate transporter (MTPPT, 
encoded in SLC25A19 gene) (6). The effect of sepsis on intes-
tinal thiamin uptake, and its influence on intestinal THTRs, 
THTR-1 and THTR-2, and MTPPT is unknown. We hypoth-
esize that sepsis produces thiamin deficiency, at least in part, 
by inhibition of thiamin uptake via suppression of intestinal 
THTRs. Furthermore, sepsis suppresses MTPPT resulting in 
reduced ATP generation. The objective of this study is to inves-
tigate in experimental model of sepsis in rats, the influence of 
sepsis and degree of severity on intestinal thiamin uptake, and 
the state of THTRs in cytoplasm and mitochondria.
MATERIAL AND METHODS
Subjects, Surgical Procedures, Animal Monitoring 
and Care
This study received approval from the Research and Develop-
ment Subcommittee on Animal Studies of the Veterans Affairs 
Long Beach Healthcare System. We studied a total of 24 male 
pathogen-free Sprague-Dawley rats randomized into groups of 
sham control, severe, moderate, and mild degree of sepsis with 
equal number of animals in each group. Sepsis was produced 
using the cecal ligation and puncture (CLP) technique (7). The 
severity of sepsis was based on the extent of cecal ligation (see 
below) (7). Surgeries were performed under general anesthe-
sia with an intramuscular mixture of ketamine hydrochloride 
100 mg/kg and xylazine 5 mg/kg. A 2-cm midline incision of 
the skin and peritoneum was made in the lower abdomen. The 
cecum was identified, withdrawn through the incision, and 
ligated below the cecal valve at 25%, 50%, and 75% of the cecal 
length with a 3-0 silk suture to define severe, moderate, and 
mild degree of sepsis, respectively. Using an 18-gauge needle, 
the cecum was perforated in two locations on the antimes-
enteric surface and was gently compressed until feces were 
extruded to ensure patency of the holes. The sham control ani-
mals underwent similar procedures without the CLP. During 
surgery, rectal temperature was monitored, and maintained at 
37°C using homeothermic warming pad (Right-Temp, Kent 
Scientific, Torrington, CT) and a heating lamp. Blood pressure 
was monitored noninvasively using the tail cuff method (CODA 
Monitor, Kent Scientific, Tomington, CT). Respiration, heart 
rate, and arterial oxygen saturation (Spo
2
) were monitored and 
displayed in real time using pulse oximeter (MouseSTAT, Kent 
Scientific). The animals were allowed to recover for 2 days. Post-
operatively, rectal temperature, blood pressure, respiration, and 
heart rate were measured twice a day. Antibiotic (gentamicin 
0.5 mg/kg IM bid), and analgesic (buprenorphine 0.05 mg/kg 
subcutaneously every 6 hr) were administered immediately 
following surgery and for 2 days. Prewarmed 0.9% NaCl at 
50 mL/kg SC was administered bid and as needed to maintain 
mean blood pressure of 70 mm Hg. Liquid acetaminophen 
0.1 mg/mL was mixed in the drinking water. Softened rat chow 
was provided liberally; however, when oral intake was poor, 
animals were hand-fed twice a day with Ensure Complete 
10 mL/kg (Abbott Nutrition, Columbus, OH). Animals that 
died, mostly because of hypotension, were replaced to main-
tain equal number of animals in each group (n = 6).
Measurement of Thiamin Uptake
After 2 days of sepsis, under general anesthesia, animals under-
went laparotomy, and thiamin uptake measurement in the 
proximal jejunum using [3H]thiamin. In vivo, two intact jeju-
nal loops (2 cm each in length) separated with another jejunal 
loop of the same length were prepared by suture ligation. In 
the first segment, 250 μL of Krebs-Ringer buffer containing 
[3H]thiamin was injected intraluminally, and in the second 
segment, labeled and unlabeled thiamin mixed with the same 
incubation medium was injected.
Uptake of [3H]thiamin (250 μM) by the carrier-mediated 
process was determined by subtracting uptake in the presence 
of a high pharmacologic concentration of unlabeled thiamin 
(1,000 μM) from uptake in its absence. Radioactivity uptake 
counting was measured after 5 minutes with Beckman Counter 
LS 6500 (Beckman Coulter, Fullerton, CA) (linear phase of 
uptake). Uptake data were expressed in fmol/mg tissue wet 
weight/5 min. All thiamin uptake experiments in septic rats 
were run simultaneously with weight-matched control rats. 
Following thiamin uptake measurements, blood sample was 
withdrawn from inferior vena cava for thiamin and cytokines 
determination. Rats were then euthanatized with pentobarbi-
tal 200 mg/kg, interperitoneally.
Determination of Thiamin Blood Concentration and 
Level of Serum Cytokines
Whole blood thiamin concentration was measured using a 
microbiological test kit with Lactobacillus fermentum–coated 
microtiter plate (ID-Vit Vitamin B1 KIF001; Institut für 
Produktqualität GmbH, Berlin, Germany). Mean reference 
value of whole blood thiamin was 48.1 ± 8.9 μg/L (± sd). Serum 
cytokines (interleukin [IL]-1β and IL-6) were measured using 
enzyme-linked immunosorbent assay kit (Thermo Fisher Sci-
entific, Grand Island, NY).
Determination of ATP
ATP in the jejunal tissue was measured colorimetrically using 
ATP assay Kit (ab83355; Abcam, Cambridge, MA) (8). Follow-
ing dissection, tissue was flash frozen by immediate immersion 
in 100% isopentane (Mallinckrodt Baker, Phillipsburg, NJ) 
prechilled on dry ice. After tissue homogenization, samples 
were then deproteinated and neutralized by adding ice-cold 
Neutralization Solution (ab93299; Abcam, Cambridge, MA) 
at 1:24 (v:v), incubating on ice for 5 minutes, centrifuging at 
10,000g for 2 minutes, and mixing with ice-cold ATP Assay 
Buffer at 1:5 (v:v). ATP standard curve was created, and ATP 
concentration in the tissue lysed from either controls or septic 
Copyright © 2016 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.
Online Laboratory Investigation
Critical Care Medicine www.ccmjournal.org 3
animals was calculated relative to the standard curve, and nor-
malized for protein concentration.
Determination of THTR-1, THTR-2, and MTPPT 
Protein and Messenger RNA (mRNA)
Frozen intestine tissues were processed for determination of 
THTR-1, THTR-2, and MTPPT protein abundance using stan-
dard western blotting. The intestine (40 mg) from the septic 
rats and paired controls was homogenized in protein buffer 
(T-PER78510; Thermo Scientific, Rockford, IL) and denatured 
for THTR-1 and THTR-2 protein analysis. Mitochondrial 
protein was extracted for MTPPT protein measurement. We 
employed Ponceau S as reference protein (9). The immunore-
active bands were analyzed using ImageQuant software, ver-
sion 5.0 (Molecular Dynamics, Sunnyvale, CA).
For mRNA extraction, approximately 30 mg frozen intestine 
tissue was homogenized in TRizol Reagent (Invitrogen, Carlsbad, 
CA) and total RNA was isolated according to the manufacturer’s 
protocol. Following reverse transcription, the mRNA expression 
level was quantified in a real-time PCR system (CFX384 Touch 
Bio-Rad Laboratories, Hercules, CA) using SYBR Green Super 
mix (Bio-Rad Laboratories), and was performed in triplicate. 18S 
was used as the housekeeping gene. Specific primers for rats are as 
follows: THTR-1: forward 5′-GATGCTCCTACGTACTGCCC-3′ 
and reverse 5′-GCAGGTAGGGAGTGAGGAAC-3′; 
THTR-2: forward 5′-TGATACTCTGCTTGTCGG- 3′ and 
reverse 5′-GTAAGAGTACGTCCAAACAG-3′; MTPPT: 
forward 5′-GGCCATACGCACCATG-3′ and reverse 
5′-GGGTCTTGCTGATGACTC-3′, and 18S: forward 
5′-GCAGAATT CCCACTCCCGACCC-3′ and reverse 
5′-CCCAAGCTCCAACTACGAGC-3′. Data were normalized to 
18S and calculated using a relative relationship method supplied 
by the manufacturer (Bio-Rad Laboratories).
Statistical Analysis
Group size was determined from thiamin uptake values from 
the initial three animals based on minimum differences in a 
mean of 0.30 and expected sd of residuals of 0.15. We required 
six animals per group to achieve a power of 0.80 and a α equal 
to 0.05 (analysis of variance [ANOVA]; SigmaPlot, version 12.0; 
SPSS, Chicago, IL). Values were expressed as mean ± se unless 
specifically indicated. A two-way ANOVA was used to com-
pare physiologic variables among groups using the appropriate 
grouping variables of time (baseline and day 2) and severity of 
sepsis (mild, moderate, and severe as defined above). For other 
variables, one-way ANOVA was used for comparison among 
groups. When the f value was significant, post hoc analysis was 
performed using the Tukey test for pairwise multiple compari-
sons. Group differences were considered significant at p value 
less than or equal to 0.05.
RESULTS
The sepsis model employed in the present study resulted in 
animal survival rate of 100%, 90%, 86%, and 75% in sham 
control, mild, moderate, and severe sepsis groups, respectively. 
At baseline, compared with controls, body weight (BW), mean 
blood pressure, heart rate, respiratory rate, and Spo
2
 were simi-
lar among groups, except body temperature was higher in all 
of the sepsis groups (Table S1, Supplemental Digital Content 
1, http://links.lww.com/CCM/B829). After 2 days, BW tended 
to decrease in moderate and severe sepsis. Body temperature 
returned to levels that of controls, likely related to antibiotic 
administration. Hemodynamic, respiratory, and oxygen-
ation variables were stable. The degree of proinflammatory 
cytokines (IL-1β and IL-6) production is a function of sepsis 
severity (Table 1). Thiamin blood concentration in the septic 
animals was not significantly different from controls (Table 1).
Carrier-mediated thiamin uptake was reduced significantly 
in proportion to the severity of sepsis (Fig. 1). This was further 
supported by the significant correlation coefficient between 
thiamin uptake and IL-1β (r2, 0.58; p < 0.001) and IL-6 
(r2, 0.67; p < 0.001) (Fig. S1, Supplemental Digital Content 1, 
http://links.lww.com/CCM/B829). As thiamin pyrophosphate 
TABLE 1. Serum Cytokines, Whole Blood Thiamin Concentration, and Intestine Adenosine 
Triphosphate in Control and Septic Animals
Variables Control
Sepsis
Mild Moderate Severe
IL-1β (pg/mL) 5.5 ± 1.4 38.4 ± 2.9 47.2 ± 6.6 148.9 ± 24.7a
IL-6 (pg/mL) 11.8 ± 4.6 78.4 ± 15.8 143.8 ± 12.8b 465.1 ± 46.2a
Thiamin (μg/L)c 51.9 ± 1.1 52.5 ± 0.8 51.1 ± 1.3 50.6 ± 0.3
Adenosine triphosphate (nmol/mg protein) 12.9 ± 1.4 10.9 ± 1.1 6.2 ± 0.4d,e 5.4 ± 0.4d,f
IL = interleukin.
a p < 0.001 severe sepsis compared with control, mild, and moderate sepsis.
b p < 0.008 moderate sepsis compared with control.
c Thiamin blood concentration n = 4.
d p < 0.001 severe and moderate sepsis compared with control.
e p = 0.01 moderate compared with mild sepsis.
f p = 0.003 severe compared with mild sepsis.
Values are mean ± se; n = 6.
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is essential for the conversion of pyruvate to acetyl-CoA in the 
generation of ATP, the reduced intestinal thiamin uptake led to 
a significantly decreased ATP in the moderate and severe sepsis 
groups, by 52% and 58%, respectively (Table 1).
The uptake of thiamin in the intestine is an active process 
mediated via cell membrane THTR-1 and THTR-2. As dem-
onstrated in Figure 2, sepsis decreased both THTR-1 and 
THTR-2 proteins significantly. Similarly, sepsis suppressed 
both THTR-1 and THTR-2 mRNA expressions (Fig. 3). The 
active form of thiamin, thiamin pyrophosphate, also requires a 
carrier-mediated transport for entry into the mitochondria. As 
shown in Figure 4, sepsis significantly reduced MTPPT protein 
and suppressed its mRNA expressions.
DISCUSSION
Sepsis is a systemic inflammatory response to infection with 
a prevalence for severe sepsis of 25–44% and a mortality rate 
of approximately 30% or greater (10). Few observational stud-
ies in critically ill patients have identified sepsis (2–4) as an 
important risk factor contributing to thiamin deficiency, and 
that the combined sepsis and thiamin deficiency was associ-
ated with higher mortality than sepsis alone (3). The present 
study is the first to demonstrate that 1) sepsis inhibited intes-
tinal carrier-mediated thiamin uptake, and the inhibition was 
in proportion to the severity of sepsis (Fig. 1); 2) both THTR 
proteins and mRNA expression levels were suppressed (Figs. 2 
and 3, respectively); and most importantly, 3) MTPPT protein 
and mRNA expressions were markedly decreased and asso-
ciated with proportionate reduction in ATP in animals with 
moderate and severe sepsis.
Our animal model of sepsis mimicked human sepsis. The 
mortality rate of animals with severe sepsis was 25%, close to 
that reported mortality in human with sepsis (10). In contrast 
to a similar rat model of severe sepsis of 2 days duration, the 
present study had a significantly lower mortality rate of 25% 
compared with 70% as previously reported after 2 days of 
induced sepsis, 25% versus 70%, respectively (7). The reduced 
Figure 1. Intestinal carrier-mediated thiamin uptake. Thiamin uptake 
expressed as percent of controls. Values are mean ± se; n = 6 for 
each group. *p < 0.001: severe compared with mild sepsis and control; 
moderate compared with mild sepsis and control. †p = 0.003: severe 
compared with moderate sepsis. #p = 0.001: mild sepsis compared with 
control.
Figure 2. Thiamin transporter (THTR)-1 (A) and THTR-2 (B) proteins. Values are mean ± se; n = 4 for each group. Representative gel images of 
respective proteins of different groups were obtained from the same gel. THTR-1: *p = 0.002 severe compared with control. *p = 0.004 moderate sepsis 
compared with control. ‡p = 0.027 mild sepsis compared with control. THTR-2: *p = 0.002 severe sepsis compared with control. *p = 0.006 moderate 
sepsis compared with control. ‡p = 0.047 mild sepsis compared with control.
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mortality rate in our study was likely related to the use of sys-
temic antibiotic administered immediately following surgery 
and maintained for 2 days.
Gut-derived sepsis, the sepsis model employed, has been 
shown to impair intestinal epithelial barrier function to pro-
mote bacterial translocation into the systemic circulation with 
subsequent bacteremia, and pathologic inflammation of the 
intestinal mucosa (11). Whether inflammation of the intestinal 
mucosa alone with or without adherence of the organisms to 
the intestinal epithelium is a requirement for thiamin uptake 
inhibition is unclear. Previous in vitro studies from our labo-
ratory demonstrated that exposure of human-derived intesti-
nal epithelial cells to enteropathogenic Escherichia coli (12) or 
toxin-producing E. coli (13) resulted in significant inhibition of 
Figure 3. Thiamin transporter-1 (A) and thiamin transporter-2 (B) messenger RNA (mRNA). Values are mean ± se; n = 4 for each group. Thiamin 
transporter-1: *p < 0.001 severe and moderate sepsis compared with control. *p = 0.001 mild sepsis compared with control. ‡p = 0.026 severe 
compared with mild sepsis. Thiamin transporter-2: *p < 0.01 severe and moderate sepsis compared with control. *p = 0.005 mild sepsis compared  
with control.
Figure 4. Mitochondrial thiamin pyrophosphate transporter (MTPPT) protein (A) and messenger RNA (mRNA) (B). Values are mean ± se; n = 4 for each 
group. Representative gel images of MTPPT proteins of different groups were obtained from the same gel. MTPPT protein: ‡p = 0.028 severe sepsis 
compared with control. ‡p = 0.022 moderate sepsis compared with control. Mitochondrial pyrophosphate transporter mRNA: *p < 0.001 severe sepsis 
compared with control. *p = 0.004 moderate sepsis compared with control. ‡p = 0.021 severe compared with mild sepsis.
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thiamin uptake. Notwithstanding the mechanisms of intestinal 
thiamin uptake inhibition, the present study demonstrated that 
sepsis is an important risk factor for the development of thia-
min deficiency as previously reported in critically ill patients 
(2, 4). Sepsis not only inhibited intestinal thiamin uptake and 
transporters, but the inhibition was a function of sepsis sever-
ity. Keeping with previous report in severe septic patients (4), 
the prevalence of thiamin deficiency was very high at 70%.
Thiamin uptake inhibition in sepsis was also associated with 
THTR-1 and THTR-2, as well as MTPPT suppression at the 
protein and mRNA levels (Figs. 2–4). With respect to mRNA 
suppression, it is unclear at present whether the reduction in 
mRNA of these transporters is mediated at the transcriptional 
and/or posttranscriptional levels (e.g., changes in mRNA sta-
bility). Further studies are needed to address these issues.
Compared with controls, the significant inhibition of 
carrier-mediated thiamin uptake in the septic animals was 
not associated with reduced blood thiamin concentration or 
thiamin deficiency. This observation was not surprising as 
our animal model of sepsis was maintained for only 2 days, 
shorter than thiamin biologic half-life of 9–18 days (14). 
Additionally, unlike critically ill patients with sepsis whose 
premorbid conditions may be associated with thiamin defi-
ciency (e.g., chronic alcoholism [15], diabetes [16], celiac dis-
ease [17], or long-term use of furosemide diuretic [18]), our 
animals were healthy prior to the induction of sepsis. Our 
observation suggests that a normal thiamin blood level in 
sepsis does not preclude functional thiamin deficiency state, 
defined as inhibition of carrier-mediated thiamin uptake 
associated with suppression of THTRs in the cell membrane 
and mitochondria. Yet, in preexisting thiamin deficiency, the 
effect of sepsis on carrier-mediated thiamin uptake and its 
transporters is unknown and requires further study. This is 
because adaptive regulation to thiamin deficiency occurs. In 
mice fed with thiamin-deficient diet, carrier-mediated thia-
min uptake was upregulated as a result of increased expres-
sions of THTR-2 at both the protein and mRNA levels, 
without changes in THTR-1 expressions (19). Depending 
on sepsis severity, it is possible that in preexisting thiamin 
deficiency, carrier-mediated thiamin uptake and THTR-2 
expression may be preserved. However, the septic-induced 
suppression of THTR-1 as shown in the present study may 
offset the adaptive regulation of THTR-2.
Sepsis did not only depressed THTR-1 and THTR-2, but 
also reduced the expression of MTPPT considerably in both 
the moderate and severe sepsis groups (Fig. 4). In the mito-
chondria, thiamin pyrophosphate is a cofactor for pyruvate 
dehydrogenase in the conversion of pyruvate to acetyl-CoA, 
and α-ketoglutarate dehydrogenase in the conversion of 
α-ketoglutarate to succynil-CoA in the tricarboxylic acid cycle 
(Krebs cycle) for the generation of ATP. Our study showed a 
significantly reduced ATP generation in animals with mod-
erate and severe sepsis. While sepsis itself, via oxidative stress 
(11), inhibits electron transport chain complexes activity (20), 
another pathway for ATP generation independent of thiamin; 
in the present study, the reduced MTPPT protein or mRNA 
expressions contributed to the reduced ATP production. Levels 
of MTPPT protein and mRNA expressions were responsible 
for 50% of the variance in ATP production as shown in the sig-
nificant correlation between ATP production and MTPPT pro-
tein and mRNA expression levels (r2, 0.50; p < 0.01 for MTPPT 
protein; and r2, 0.54; p < 0.01 for MTTPT mRNA expression).
ATP is essential to provide energy for numerous cellular 
processes and reactions (21), particularly in the metaboli-
cally active cells such as the intestine for nutrient absorption. 
As sepsis is a systemic inflammatory syndrome, the reduced 
ATP generation may not be limited to the intestinal epithelial 
cells, but may involve other organs via similar mechanism of 
impaired transport of thiamin pyrophosphate into the mito-
chondria. Further research is needed to investigate the role of 
sepsis on functional thiamin deficiency with its consequence of 
ATP depletion in other organs such as the brain in the mani-
festation of sepsis-induced delirium (22), or in the peripheral 
nerves and skeletal muscles in sepsis-induced ICU-acquired 
muscle weakness.
Limitation of the Study
We defined severity of sepsis according to the site of cecal liga-
tion and not according to the extent of organ failure or tis-
sue hypoperfusion as clinically defined (23). However, animals 
with severe sepsis had the highest mortality and associated 
with the highest proinflammatory cytokines levels (Table 1) 
supporting the severity of sepsis. The duration of sepsis was 
limited to 2 days. A temporal relationship between duration of 
sepsis and progression of thiamin deficiency is unknown, and 
requires further study.
Our measurement of thiamin was obtained from whole 
blood using microbiological test method rather than using 
high-performance liquid chromatography as used clinically 
(24); however, performance of these two methods is compa-
rable (25).
Clinical Implication
Alcoholism has been implicated as the most common predis-
posing factor for thiamin deficiency with its complications 
of Wernicke-Korsakoff syndrome and peripheral neuropathy 
(26). As reported in previous clinical studies (2–5), the results 
of our study confirmed that sepsis, particularly severe sepsis, 
is an important risk factor for the development of functional 
thiamin deficiency via, at least in part, inhibition of carrier-
mediated intestinal thiamin uptake. Normal thiamin blood 
concentration does not preclude functional thiamin deficiency 
in specific organ. In sepsis, reduced thiamin blood concentra-
tion suggests a late manifestation of thiamin deficiency state 
and may portend a poor prognosis. Further prospective study 
is needed to confirm this contention.
CONCLUSION
Sepsis induced inhibition of intestinal thiamin uptake; the 
inhibition was a function of sepsis severity. Sepsis also sup-
pressed THTRs (THTR-1 and THTR-2) and MTPPT, leading 
to a significant reduction in ATP.
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